ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för daclatasvir. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

19 träffar

Bibliografisk träff 2014-11-03

Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition.

Nettles JH, Stanton RA, Broyde J, Amblard F, Zhang H, Zhou L, Shi J, McBrayer TR, Whitaker T, Coats SJ, Kohler JJ, Schinazi RF.

J Med Chem · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1021/jm501291c

Bibliografisk träff 2014-10-13

Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.

Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA.

Gastroenterology · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1053/j.gastro.2014.10.007

Bibliografisk träff 2014-09-01

The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.

Eley T, Sevinsky H, Huang SP, He B, Zhu K, Kandoussi H, Gardiner D, Grasela DM, Bertz R, Bifano M.

Clin Drug Investig · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1007/s40261-014-0219-9

Bibliografisk träff 2014-09-01

Daclatasvir + asunaprevir: first global approval.

Poole RM.

Drugs · journal article · DOI 10.1007/s40265-014-0279-4

Bibliografisk träff 2014-07-30

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S.

Gut · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1136/gutjnl-2014-307498

Bibliografisk träff 2014-04-10

Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection.

Miura M, Maekawa S, Sato M, Komatsu N, Tatsumi A, Takano S, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Enomoto N.

Hepatol Res · journal article · DOI 10.1111/hepr.12316

Bibliografisk träff 2014-03-05

Approaches to hepatitis C treatment and cure using NS5A inhibitors.

Kohler JJ, Nettles JH, Amblard F, Hurwitz SJ, Bassit L, Stanton RA, Ehteshami M, Schinazi RF.

Infect Drug Resist · review-article; review; journal article · DOI 10.2147/idr.s36247

Bibliografisk träff 2014-01-22

Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.

McPhee F, Hernandez D, Zhou N, Yu F, Ueland J, Monikowski A, Chayama K, Toyota J, Izumi N, Yokosuka O, Kawada N, Osaki Y, Hughes EA, Watanabe H, Ishikawa H, Kumada H.

Antivir Ther · research support, non-u.s. gov't; journal article · DOI 10.3851/imp2729

Bibliografisk träff 2014-01-22

A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.

Suzuki F, Toyota J, Ikeda K, Chayama K, Mochida S, Hayashi N, Ishikawa H, Miyagoshi H, Hu W, McPhee F, Hughes EA, Kumada H.

Antivir Ther · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.3851/imp2730

Bibliografisk träff 2014-01-22

Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.

Izumi N, Yokosuka O, Kawada N, Osaki Y, Yamamoto K, Sata M, Ishikawa H, Ueki T, Hu W, McPhee F, Hughes EA, Kumada H.

Antivir Ther · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.3851/imp2731

Bibliografisk träff 2014-01-01

Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.

Gentile I, Borgia F, Coppola N, Buonomo AR, Castaldo G, Borgia G.

Curr Med Chem · review; journal article · DOI 10.2174/0929867321666131228222215

Bibliografisk träff 2013-12-17

Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.

Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D, Bertz R.

Antivir Ther · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.3851/imp2718

Bibliografisk träff 2013-10-29

Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration.

Ke R, Loverdo C, Qi H, Olson CA, Wu NC, Sun R, Lloyd-Smith JO.

J Antimicrob Chemother · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1093/jac/dkt423

Bibliografisk träff 2013-08-09

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.

Herbst DA, Reddy KR.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2013.826189

Bibliografisk träff 2013-05-14

A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir.

O'Boyle DR, Nower PT, Sun JH, Fridell R, Wang C, Valera L, Gao M.

J Virol Methods · journal article · DOI 10.1016/j.jviromet.2013.04.024

Bibliografisk träff 2013-02-19

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.

Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS.

Proc Natl Acad Sci U S A · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1073/pnas.1203110110

Bibliografisk träff 2013-02-12

Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.

Wang C, Sun JH, O'Boyle DR, Nower P, Valera L, Roberts S, Fridell RA, Gao M.

Antimicrob Agents Chemother · controlled clinical trial; research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.02494-12

Bibliografisk träff 2013-02-01

HCV NS5A inhibitors in development.

Suk-Fong Lok A.

Clin Liver Dis · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.cld.2012.09.006

Bibliografisk träff 2012-10-22

In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.

Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA.

Antimicrob Agents Chemother · brief-report; journal article · DOI 10.1128/aac.01874-12